The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 31 March 2026•Updated 31 March 2026•

1 min read

Nuwellis Pediatric Segment Reaches 50% of Total U.S. Revenue in 2025

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Key Facts

1Nuwellis' pediatric category achieved approximately 50% of total U.S. revenue in 2025.

2 months ago

Version History

Version 12 months ago

What changed: The story was updated to include the significant stock decline, current profit margins, revenue growth forecasts for 2026, and valuation insights from InvestingPro.

Nuwellis (NUWE) reported that its pediatric segment contributed approximately 50% of its total U.S. revenue in 2025, supported by an operational network of 47 medical centers. Despite this strategic milestone, the company's stock has faced significant pressure, experiencing a 97% decline over the past year. While Nuwellis maintains a robust gross profit margin of 62%, the firm remains currently unprofitable as it continues to scale its specialized healthcare solutions. Looking forward, analysts forecast a revenue growth of 9% for the 2026 fiscal year. Furthermore, data from InvestingPro suggests that the stock may currently be undervalued relative to its intrinsic potential. This combination of high-margin specialized growth and current market volatility presents a complex valuation outlook for investors.